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Abstract The aim of the present study was to investigate
the potential synergy between meropenem and lev-
ofloxacin in vitro and in experimental meningitis and to
determine the effect of meropenem on levofloxacin-
induced resistance in vitro. Meropenem increased the
efficacy of levofloxacin against the penicillin-resistant
pneumococcal strain KR4 in time-killing assays in vitro
and acted synergistically against a second penicillin-
resistant strain WB4. In the checkerboard, only an
additive effect (FIC indices: 1.0) was observed for both
strains. In cycling experiments in vitro, levofloxacin alone
led to a 64-fold increase in the MIC for both strains after
12 cycles. Addition of meropenem in sub-MIC concen-
trations (0.25MIC) completely inhibited the selection of
levofloxacin-resistant mutants in WB4 after 12 cycles. In
KR4, the addition of meropenem led to just a twofold
increase in the MIC for levofloxacin after 12 cycles.
Mutations detected in the genes encoding for topoiso-
merase IV (parC) and gyrase (gyrA) confirmed the
levofloxacin-induced resistance in both strains. Addition
of meropenem was able to completely suppress lev-
ofloxacin-induced mutations in WB4 and led to only one
mutation in parE in KR4. In experimental meningitis,
meropenem, given in two doses (2125 mg/kg), produced
a good bactericidal activity (0.45 Dlog10 cfu/ml·h)
comparable to one dose (110 mg/kg) of levofloxacin
(0.44 Dlog10 cfu/ml·h) against the penicillin-resistant
strain WB4. Meropenem combined with levofloxacin
acted synergistically (0.93 Dlog10 cfu/ml·h), sterilizing
the CSF of all rabbits.
Introduction
For clinicians and infectiologists, the worldwide increase
in penicillin-resistant pneumococci remains a matter of
major concern. In the USA, the resistance rates increased
rapidly over the past years, reaching 33% in 1999 [1]. In
some cases, additional resistance to cephalosporins has
further reduced the therapeutic options for infections with
penicillin-resistant strains. Besides increasing isolation of
quinolone-resistant strains in several countries [2, 3, 4],
more alarming is the report of treatment failure with
quinolones due to the emergence of resistance during
treatment [5]. Until now, b-lactam antibiotics have
remained the drugs of choice for pneumococcal infec-
tions, except when their penetration into infected tissues
is limited, as is the case in meningitis. Based on actual
recommendations, a combination of a cephalosporin with
vancomycin is recommended for meningitis due to
resistant strains [6]. However, the efficacy of this
antibiotic regimen might be jeopardized, since vancomy-
cin- and cephalosporin-tolerant pneumococci associated
with treatment failures have been isolated recently [7]. A
potent antibiotic regimen that does not lead to emergence
of resistance would represent a major progress. Meropen-
em is a carbapenem with a broad antibacterial spectrum
and a good activity against penicillin-resistant pneumo-
cocci in experimental meningitis [8].
In this study we have investigated the potential
synergy between meropenem and levofloxacin in vitro
and in experimental meningitis and the effect of
meropenem on levofloxacin-induced resistance in vitro.
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Materials and Methods
Study Strains and Determination
of Minimal Inhibitory Concentrations
The two pneumococcal strains (WB4 and KR4) were originally
isolated from two patients with pneumonia at the University
Hospital of Bern, Switzerland. The MICs for WB4 were as follows:
penicillin 4 mg/l, ceftriaxone 0.5 mg/l, meropenem 0.5 mg/l,
vancomycin 0.12–0.25 mg/l, levofloxacin 1 mg/l, gatifloxacin 0.12–
0.25 mg/l, moxifloxacin 0.12 mg/l, and garenoxacin 0.03 mg/l. The
MICs of KR4 were as follows: penicillin 4 mg/l, ceftriaxone
0.5 mg/l, meropenem 0.5 mg/l, vancomycin 0.12–0.25 mg/l, levo-
floxacin 1 mg/l, gatifloxacin 0.25 mg/l, moxifloxacin 0.12 mg/l,
and garenoxacin 0.015 mg/l.
MICs were determined by the macrodilution broth method. The
MIC was defined as the lowest concentration that inhibited visible
growth after 12 and 24 h of incubation at 37C.
Rabbit Meningitis Model
The meningitis model, originally described by Dacey and Sande [9]
was used in this study. The experimental protocol was accepted by
the local ethical committee (Veterinramt des Kantons Bern).
Young New Zealand White rabbits weighing 2–2.5 kg were
anesthetized by intramuscular injections of ketamine (30 mg/kg)
and xylazine (15 mg/kg) and were immobilized in stereotactic
frames for induction of meningitis and sampling of colony-forming
units (cfu). An inoculum containing approximately 105 cfu of
penicillin-resistant strain WB4 was instilled in the cisterna magna.
A long-acting anesthetic drug (ethylcarbamate [urethane]: 3.5 g/
rabbit) was injected subcutaneously, and animals were returned to
their cages. Fourteen hours later a catheter was introduced into the
femoral artery for serum sampling, and the cisterna magna was
punctured again for periodic CSF sampling before and 1, 2, 4, 5, 6,
and 8 h after initiation of therapy. Anesthesia was performed by
repetitive injections of pentobarbital sodium. Blood samples for
measuring meropenem and levofloxacin concentrations were drawn
at 0.25, 0.5, 1, 1.5, 2, 3, 4, 4.25, 4.5, 5, 6, and 8 h after antibiotic
administration. Antibiotics were administered by a peripheral ear
vein at the following concentrations: meropenem 125 mg/kg and
levofloxacin 10 mg/kg of body weight. Meropenem was injected at
hours 0 and 4 and levofloxacin only at hour 0. All antibiotics and
anesthetic drugs were purchased commercially.
Bacterial titers were measured by 10-fold serial dilutions of
CSF samples, plated on blood agar plates containing 5% sheep
blood, and incubated overnight at 37C. In parallel, 20 l of
undiluted samples were plated (limit of detectability: 50 cfu/ml).
Comparison between dilutions of CSF was used to exclude
significant carryover effects during therapy. The antimicrobial
activity of the different regimens during the 8-h treatment was
calculated by linear regression analysis and expressed as change in
log10 cfu per milliliter per hour and as change of viable count over
8 h. A value of 1.7 (log10 of the limit of detectability) was assigned
to the first sterile CSF sample, and a value of 0 was assigned to any
following sterile CSF sample. The results are expressed as means €
standard deviation. Statistical significance was determined by the
Newman-Keuls test.
Determination of Antibiotic Levels in Cerebrospinal Fluid
Antibiotic concentrations in the CSF were measured by the agar
diffusion method. Standard curves were performed in saline with
5% rabbit serum in order to mimic CSF protein concentration [10].
Bacillus subtilis ATCC 6633 was used as test strain for lev-
ofloxacin and meropenem [11]. The inter- and intraday variability
was approximately 10%. The limits of detection were 0.3 mg/l for
meropenem and for levofloxacin.
In Vitro Killing Assays
The two pneumococcal strains (WB4 and KR4) were grown in C+Y
medium [12] to an optical density of 0.3 at 590 nm and then diluted
40-fold to 106 cfu, corresponding approximately to the CSF
bacterial titer in rabbits before initiation of therapy. Meropenem
was added in sub-MIC concentrations (0.5MIC against KR4 and
WB4) and levofloxacin in concentrations corresponding to the
MIC. Bacterial titers were determined at 0, 2, 4, 6, and 8 h by serial
dilution of samples, plated on agar plates containing 5% sheep
blood, and incubated at 37C for 24 h. Experiments were performed
in triplicate, and results are expressed as means € standard
deviation. Synergy was defined as the bactericidal activity of a
combination regimen significantly superior to the sum of each
substance.
Determination of Fractional Inhibitory Concentration Index
Fractional inhibitory concentration (FIC) indices were measured
using the checkerboard method as described previously [13]. In
brief, the two pneumococcal strains (WB4 and KR4) were grown in
C+Y medium until the logarithmic growth phase (optical density
0.3 at 590 nm) and were then diluted 1:40. Approximately 0.5–
1106 cfu were pipetted into microtiter trays containing concen-
trations of levofloxacin and meropenem that ranged from
0.03125MIC to 2MIC. Microtiter plates were incubated at
37C for 24 h. After 6, 12, and 24 h, the plates were read for
detection of inhibition of bacterial growth. The experiments were
performed in duplicate and were repeated once. FIC indices were
calculated by the method of Eliopoulos and Moellering [14].
Synergy was defined as an FIC index of 0.5, additivity was
defined as an FIC index of >0.5–4, and antagonism was defined
as an FIC index of >4.
Selection of Quinolone-Resistant Derivatives in Vitro
Experiments were designed to test the tendency of levofloxacin to
select resistant strains in liquid cultures. Large inocula (107–
108 cfu/ml) of either WB4 or KR4 were exposed to stepwise
increasing concentrations of antibiotics [15]. Series of tubes
containing twofold increasing concentrations of levofloxacin were
incubated either with WB4 or KR4 (107–108 cfu/ml), as for MIC
determination. After 12 h of incubation, 0.1-ml samples from the
tubes containing the highest antibiotic concentration and still
showing turbidity were used to inoculate a new series of tubes
containing serial dilutions of antibiotic. The experiments were
performed during 12 cycles. The MIC was determined after each
cycle.
In parallel, the same experimental protocol was used, but
meropenem was added in low concentrations (0.12 mg/l, corre-
sponding to 0.25MIC for the 2 strains) to the tubes containing
serial dilutions of levofloxacin. After 12 h of incubation, the MIC
was determined as described above in tubes containing only
levofloxacin.
Preparation of Chromosomal DNA, PCR Amplification,
and DNA Sequence Analysis
Chromosomal pneumococcal DNA was prepared as described [16].
PCR-amplification of the parC, parE, gyrA, and gyrB genes was
performed according to a published method [17]. PCR amplifica-
tion was performed with a GeneAmp PCR system 9,700 apparatus
(Perkin Elmer, USA). After amplification, PCR products were
purified by using a QIAquick PCR purification kit (Quiagen,
Switzerland). Nucleotide sequencing for the PCR amplicons was
carried out by using the ABI PRISM Dye Terminator Cycle
Sequencing Ready Reaction kit according to the protocol of the
manufacturer (Perkin Elmer). An ABI PRISM 377 DNA sequencer
was used for sequencing. All testing was performed in duplicate.
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Results
In time-killing assays, the antibiotics were used at
concentrations producing only negligible antibacterial
activity when used as monotherapies (meropenem:
0.5MIC, levofloxacin 1MIC) in order to detect poten-
tial synergy between the antibiotics. Against WB4,
0.5MIC of meropenem did not produce any bactericidal
activity, with bacterial titers comparable to the untreated
controls after 8 h (Fig. 1). Levofloxacin (1MIC) led to a
decrease in the viable cell counts of around 3 log10 cfu/ml
over 8 h. The combination regimen acted synergistic and
managed to sterilize the cultures already after 4 h. Against
KR4, 0.5MIC of meropenem produced a negligible
decrease in the bacterial titer (0.7 log10 cfu/ml over 8 h).
Levofloxacin monotherapy (1MIC) produced an anti-
bacterial effect of 3 log10 cfu/ml over 8 h. Due to the
mean variation of the test system, the combination
treatment was only additive (Fig. 2). Synergy was defined
as bactericidal effect of a drug combination significantly
exceeding the sum of the bactericidal effects of each
agent alone [18]. In the checkerboard, the effect of the
combination was only additive, with FIC indices of 1 for
both strains.
On the basis of on a previously described protocol
[19], levofloxacin-resistant mutants were selected by
sequential incubation of both pneumococcal strains with
different levofloxacin concentrations during 12 cycles. In
WB4, the MIC of levofloxacin increased to 8 mg/l already
after two cycles and reached 64 mg/l after six cycles,
remaining stable during the last cycles. The addition of
meropenem in sub-MIC concentration (0.25MIC) com-
pletely impeded levofloxacin-induced resistance over 12
cycles (Fig. 3). The stepwise increase in the MIC by
sequential incubation with levofloxacin correlated with
mutations detected in the two target genes that led to
amino acid changes in the subunits of the enzymes
(Ser79!Tyr in ParC and Glu85!Lys in GyrA; Table 1).
With the combination regimen, no mutation was detected.
With the second strain (KR4), the development of
levofloxacin-induced resistance occurred in a similar
way. The MIC of levofloxacin increased eightfold after
two cycles and 64-four-fold after eight cycles, remaining
stable until the end of the experimental period (Fig. 4).
The addition of meropenem led to a twofold increase in
the MIC of levofloxacin for KR4, occurring after nine
cycles. Levofloxacin monotherapy induced two mutations
in parC (Ser79!Tyr and Asp83!Tyr) and one mutation
in gyrA (Glu85!Lys). With the combination regimen,
only one mutation was detected in parE (Asp435!Asn).
It is interesting to note that the addition of meropenem in
low concentrations (0.25MIC) did not influence the MIC
of levofloxacin. No cross-resistance between meropenem
and levofloxacin was observed. Sequential incubation of
Fig. 1 Killing rates of meropenem (MPM 0.5MIC), levofloxacin
(LVX 1MIC), and meropenem combined with levofloxacin
(MPM+LVX) for the penicillin-resistant strain WB4. Experiments
were performed in triplicate, and killing rates were expressed as
means € standard deviation
Fig. 2 Killing rates of meropenem (MPM 0.5MIC), levofloxacin
(LVX 1MIC), and meropenem combined with levofloxacin
(MPM+LVX) for the penicillin-resistant strain KR4. Experiments
were performed in triplicate, and killing rates were expressed as
means € standard deviation
Fig. 3 Selection of levofloxacin-resistant mutants of Streptococcus
pneumoniae WB4 exposed to stepwise increasing concentrations of
levofloxacin alone or in combination with a sub-MIC concentration
(0.25MIC) of meropenem
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the two pneumococcal strains with levofloxacin did not
change the MIC of meropenem (Table 2).
The kinetics of the antibiotics is described in Fig. 5 and
Fig. 6. Fifteen minutes after the first dose (125 mg/kg) of
meropenem, serum levels peaked at 70 mg/l and
decreased slowly to 1.5 mg/l 4 h later. The second
injection led to peak levels around 110 mg/l, declining to
2.0 mg/l after the end of the treatment period (data not
shown). In the CSF, meropenem levels ranged between
4.7 and 1.3 mg/l and between 5.4 and 1.25 mg/l after the
second injection (Fig. 5). During the entire treatment
period, meropenem CSF levels remained above the MIC
(0.5 mg/l for WB4).
One injection of levofloxacin (10 mg/kg) led to serum
peak levels around 19 mg/l after 15 min, decreasing
slowly to 9 mg/l after 2 h, to 6.1 mg/l after 4 h, and to
4 mg/l after 6 h. At the end of the treatment, the serum
levels ranged around 1.2 mg/l (data not shown). In the
CSF, the peak levels reached 3.4 mg/l, decreasing
continuously to 1.05 mg/l at the end of the experiment
(Fig. 6). The levofloxacin CSF levels remained above the
MIC (0.5 mg/l) during the entire treatment period.
The antibacterial activity of the different regimens in
the experimental meningitis model is presented in Table 3.
In untreated controls, bacterial titers remained more or
less stable, increasing only marginally during 8 h
(+0.28€0.11 log10 cfu/ml). Meropenem monotherapy
produced a good antibacterial activity (0.45€0.12
Dlog10 cfu/ml.h), sterilizing the CSF of two of eight
rabbits at the end of the treatment period. Levofloxacin
monotherapy produced similar killing rates (0.44€0.13
Table 1 Mutations in topoiso-
merase IV (ParC and ParE) and
gyrase (GyrA and GyrB) before
and after cyclic exposure to
levofloxacin (LVX) alone or in
combination with meropenem
(MPM) in two penicillin-resis-
tant pneumococcal strains
(WB4 and KR4)
Strain ParC ParE GyrA GyrB
WB4 none none none none
WB4 + LVX 79Ser !Phe none 85Glu !Lys none
WB4 + (LVX + MPM) none none none none
KR4 none none none none
KR4 + LVX 79Ser !Phe none 85Glu !Lys none
83Asp !Tyr
KR4 + (LVX+ MPM) none 435Asp !Asn none none
Table 2 MICs of levofloxacin (LVX) alone and in combination with subinhibitory concentrations of meropenem (MPM) for two
penicillin-resistant strains (WB4 and KR4)
MIC (mg/l)
WB4 WB4 LVX WB4 LVX + MPM KR4 KR4 LVX KR4 LVX + MPM
Levofloxacin 1 64 1 1 64 2
Meropenem 0.5 0.5 0.5 0.5 0.5 0.5
WB4, quinolone-susceptible but penicillin-resistant parent pneumococcus (MIC, 4 mg/l); WB4 LVX, levofloxacin-resistant derivative
selected by passages on this drug, KR4, quinolone-susceptible but penicillin-resistant parent pneumococcus (MIC, 4 mg/l); KR4 LVX,
levofloxacin-resistant derivative selected by passages on this drug; WB4 LVX + MPM or KR4 LVX + MPM, same as above, cycled in the
presence of subinhibitory concentrations of meropenem
Fig. 4 Selection of levofloxacin resistant mutants of Streptococcus
pneumoniae KR4 exposed to stepwise increasing concentrations of
levofloxacin alone or in combination with a sub-MIC concentration
(0.25MIC) of meropenem
Fig. 5 Meropenem CSF concentrations after two injections of
meropenem (125 mg/kg). The concentration of meropenem
remained above the MIC (0.5 mg/l) throughout the treatment period
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Dlog10 cfu/ml.h) and sterilized the CSF of one of eight
rabbits. The combination treatment (levofloxacin com-
bined with meropenem) was highly efficacious
(0.93€0.14 Dlog10 cfu/ml.h) and sterilized the CSF in
all rabbits. The CSF of six of eight rabbits was already
sterile after 6 h.
Discussion
Over the last decades, pneumococci have managed to
resist the action of antibiotics by developing several
mechanisms. They modified target structures, i.e. peni-
cillin-binding proteins (PBPs) to elude the effect of b-
lactam agents. To avoid the effect of quinolones, they
altered gyrase and topoisomerase IV or activated efflux
pumps, jeopardizing the efficacy of this class of antibi-
otics. Recently published reports about the emergence of
vancomycin- and cephalosporin-tolerant strains leading to
treatment failures in cases of pneumococcal meningitis
are a matter of major concern [7]. Even more alarming is
the emergence of quinolone resistance during therapy,
which limits the use of these antibiotics as monotherapy.
The aim of this study was to test a highly bactericidal
regimen for pneumococcal meningitis that might, in some
circumstances, reduce the risk of development of
quinolone-induced resistance.
In vitro, an increased efficacy of the combination was
found in time-killing assays, although the combination
showed no synergism in the checkerboard with FIC
indices of 1.0. The most striking feature of this study was
the effect of the addition of low concentrations of
meropenem on the development of levofloxacin-induced
resistance. The meropenem concentration (0.25MIC)
was chosen on the basis of results obtained with the
checkerboard method. Cycling of the two pneumococcal
strains in the presence of different concentrations of
levofloxacin led to a stepwise increase in resistance until
high-level resistance (MIC, 64 mg/l) was reached after 12
cycles for both strains. This increase in resistance is based
on point mutations in genes encoding for the two target
enzymes, i.e. topoisomerase IV (parC) and gyrase (gyrA).
The mutations presented in Table 1 have already been
described in pneumococci [17, 20, 21, 22]. On the other
hand, addition of meropenem to the same pneumococcal
cultures almost completely impeded levofloxacin-induced
resistance in WB4 during 12 cycles. In KR4, only a
twofold increase in the MIC occurred after nine cycles,
correlating with the single mutation detected in parE
(Asp435!Asn). One might speculate about the underly-
ing mechanism of this effect, but basically two scenarios
are conceivable. First, on the basis of the synergy
observed between these two antibiotics, the bacterial
population might be lowered for a longer period below
the critical level that allows selection of mutations (i.e.
below 106–108 cfu/ml). Second, the prevention of muta-
tions might be due to the combined antibacterial effect of
antibiotics with different targets (b-lactam agents and
quinolones). This hypothesis seems less likely because the
MIC of levofloxacin was not influenced by the addition of
meropenem in low concentrations, although slight inter-
action on the cellular level might be missed by the
determination of MICs.
In experimental meningitis, antibiotic doses were
chosen in order to mimic levels achieved in humans.
Two injections of 125 mg/kg of meropenem led to CSF
levels in rabbits ranging between 5.4 and 1.25 mg/l,
which correspond closely to levels obtained in humans
with bacterial meningitis (6.47–0.90 mg/l [23]). One
injection of levofloxacin in rabbits (10 mg/kg) led to
slightly higher peak levels than those measured in humans
Fig. 6 Levofloxacin CSF concentrations after one injection of
levofloxacin (10 mg/kg). The concentration of levofloxacin
remained above the MIC (1 mg/l) throughout the treatment period
Table 3 Single drug and combination therapy against penicillin-resistant Streptococcus pneumoniae WB4 in experimental meningitis
Antibiotic No. of rabbits Mean value € SD
Initial titer (log10 cfu/ml) Killing rate (Dlog10 cfu/ml·h) Killing rate/8 h (log10 cfu/ml)
Controls 5 6.05€0.50 +0.09€0.35a +0.28€0.11a
Meropenem 8 5.85€0.45 0.45€0.12b 3.80€0.90b
Levofloxacin 8 6.11€0.93 0.44€0.13b 3.40€0.66b
Levofloxacin +
meropenem
8 6.18€0.53 0.93€0.14b 6.18€0.53b
a P<0.05 versus all groups
b P<0.05, levofloxacin + meropenem versus all monotherapies
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after 500 mg b.i.d. (peak levels: 3.4 mg/l in rabbits vs.
2.56–1.29 mg/l in humans) [24].
One of the most interesting feature of this study was
the efficacy of the combination regimen compared with
the monotherapies (0.93 for the combination regimen vs.
0.45 and 0.44 Dlog10 cfu/ml·h for meropenem and
levofloxacin monotherapy, respectively). The antibacte-
rial efficacy of meropenem monotherapy was comparable
to that reported in a previously published study with the
same experimental setting [8], and levofloxacin was
slightly more efficacious, with similar peak levels in CSF
[25]. It is noteworthy that the actual combination regimen
(meropenem + levofloxacin) against the same strain WB4
was more efficacious than the standard regimen based on
ceftriaxone and vancomycin (ca. 0.50 for the standard
regimen vs. 0.9 Dlog10 cfu/ml.h for meropenem com-
bined with levofloxacin, respectively [13, 26]).
Synergy between quinolones and cell-wall-active an-
tibiotics, i.e. vancomycin, in experimental meningitis is
not new [13, 26]. In cycling experiments in vitro, we have
previously shown that vancomycin reduced ciprofloxacin-
and trovafloxacin-induced resistance in the same strain
(WB4), but at a lower order of magnitude [19].
The combination regimen based on meropenem and
levofloxacin was very efficacious in experimental men-
ingitis, sterilizing the CSF of rabbits within 6 h. This
regimen drastically reduced the risk of development of
quinolone resistance in vitro. In summary, we have
demonstrated that a combination of a broad-spectrum
carbapenem, i.e. meropenem, and a quinolone, i.e.
levofloxacin, fulfills all prerequisites of an ideal thera-
peutical regimen needed in the empiric treatment of
bacterial meningitis.
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